JP2023540081A5 - - Google Patents

Info

Publication number
JP2023540081A5
JP2023540081A5 JP2023513934A JP2023513934A JP2023540081A5 JP 2023540081 A5 JP2023540081 A5 JP 2023540081A5 JP 2023513934 A JP2023513934 A JP 2023513934A JP 2023513934 A JP2023513934 A JP 2023513934A JP 2023540081 A5 JP2023540081 A5 JP 2023540081A5
Authority
JP
Japan
Prior art keywords
alkyl
compound according
compound
ring
nitrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023513934A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023540081A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/049084 external-priority patent/WO2022051634A1/en
Publication of JP2023540081A publication Critical patent/JP2023540081A/ja
Publication of JP2023540081A5 publication Critical patent/JP2023540081A5/ja
Pending legal-status Critical Current

Links

JP2023513934A 2020-09-03 2021-09-03 キノリンcgasアンタゴニスト化合物 Pending JP2023540081A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063074446P 2020-09-03 2020-09-03
US63/074,446 2020-09-03
US202063124713P 2020-12-11 2020-12-11
US63/124,713 2020-12-11
US202163196146P 2021-06-02 2021-06-02
US63/196,146 2021-06-02
PCT/US2021/049084 WO2022051634A1 (en) 2020-09-03 2021-09-03 Quinoline cgas antagonist compounds

Publications (2)

Publication Number Publication Date
JP2023540081A JP2023540081A (ja) 2023-09-21
JP2023540081A5 true JP2023540081A5 (https=) 2024-09-10

Family

ID=78086041

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023513934A Pending JP2023540081A (ja) 2020-09-03 2021-09-03 キノリンcgasアンタゴニスト化合物

Country Status (13)

Country Link
US (3) US11873291B2 (https=)
EP (1) EP4208452A1 (https=)
JP (1) JP2023540081A (https=)
KR (1) KR20230062845A (https=)
CN (1) CN116234802A (https=)
AU (1) AU2021336977A1 (https=)
BR (1) BR112023003948A2 (https=)
CA (1) CA3191172A1 (https=)
IL (1) IL300976A (https=)
MX (1) MX2023002553A (https=)
TW (1) TW202227407A (https=)
WO (1) WO2022051634A1 (https=)
ZA (1) ZA202304064B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021209473A1 (en) * 2020-04-16 2021-10-21 F. Hoffmann-La Roche Ag Biphenyl derivatives
KR20230062845A (ko) 2020-09-03 2023-05-09 이뮨센서 테라퓨틱스, 인코포레이티드 퀴놀린 cgas 길항제 화합물
WO2022137085A1 (en) 2020-12-22 2022-06-30 Novartis Ag Indole derivatives useful in treating conditions associated with cgas
IL315346A (en) 2022-03-02 2024-11-01 Immunesensor Therapeutics Inc CGAS agonistic quinoline compounds
CN118265696A (zh) * 2022-11-07 2024-06-28 深圳博瑞医药科技有限公司 一种芳基羧酸类化合物及其制备Mrgpr X4抑制剂的用途
WO2024099135A1 (zh) * 2022-11-11 2024-05-16 杭州中美华东制药有限公司 1,5-萘啶类cGAS抑制剂及其用途
AU2024326748A1 (en) 2023-08-18 2026-04-02 Katholieke Universiteit Leuven 1,3-dihydro-2h-pyrrolo[3,4-c]quinoline derivatives as cgas inhibitors for the treatment of inflammatory and/or autoimmune diseases
GB202314609D0 (en) * 2023-09-22 2023-11-08 Univ College Cardiff Consultants Ltd Iminosugar prodrug compounds
WO2025147600A1 (en) * 2024-01-05 2025-07-10 Dewpoint Therapeutics, Inc. Amino quinoline compounds and uses thereof
WO2026057087A1 (zh) * 2024-09-14 2026-03-19 杭州英创医药科技有限公司 作为cGAS抑制剂的化合物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3542785A (en) 1967-05-15 1970-11-24 Ciba Geigy Corp 2-hydroxy-4-aryl-quinolines
US3668207A (en) 1970-01-22 1972-06-06 Ciba Geigy Corp 2-amino-4-aryl-quinolines
BR0312204A (pt) 2002-06-27 2005-04-26 Schering Ag Antagonista de receptor ccr5 de quinolina substituìda
WO2009005677A2 (en) * 2007-06-29 2009-01-08 Gilead Sciences, Inc. Antiviral compounds
CA2699697A1 (en) 2007-09-27 2009-04-02 F. Hoffmann-La Roche Ag Quinoline derivatives as 5ht5a receptor antagonists
US20190127354A1 (en) 2015-12-14 2019-05-02 Fundación Para La Investigación Médica Aplicada 2,4,6,7-tetrasubstituted quinoline compounds as inhibitors of dna methyltransferases
CN109111426B (zh) * 2017-06-23 2021-12-14 中国科学院上海药物研究所 一类稠合双环杂芳基或芳基化合物,及其用途
KR20240151869A (ko) * 2017-09-08 2024-10-18 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 Enpp1 저해제 및 암의 치료용의 이의 용도
WO2019241787A1 (en) 2018-06-15 2019-12-19 The Regents Of The University Of Colorado A Body Corporate Novel cyclic gmp-amp synthase (cgas) inhibitors and their method of use
PL3829581T3 (pl) * 2018-07-27 2024-07-01 Arcus Biosciences, Inc. Antagoniści pirydonu a2r
EP3620164A1 (en) 2018-09-05 2020-03-11 Genoscience Pharma SAS Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins b (ctsb), l (ctsl) and d (ctsd) related diseases
CA3125626A1 (en) 2019-01-04 2020-07-09 Bellbrook Labs, Llc Inhibitors of cgas activity as therapeutic agents
US11245538B2 (en) * 2019-09-28 2022-02-08 Intel Corporation Methods and apparatus to aggregate telemetry data in an edge environment
AU2021211437A1 (en) 2020-01-20 2022-09-15 Crescenta Biosciences Novel cell metabolism modulating compounds and uses thereof
WO2022010948A1 (en) 2020-07-06 2022-01-13 Crescenta Biosciences Novel cell metabolism modulating compounds and uses thereof for the treatment of viral diseases
KR20230062845A (ko) 2020-09-03 2023-05-09 이뮨센서 테라퓨틱스, 인코포레이티드 퀴놀린 cgas 길항제 화합물
IL315346A (en) 2022-03-02 2024-11-01 Immunesensor Therapeutics Inc CGAS agonistic quinoline compounds

Similar Documents

Publication Publication Date Title
JP2023540081A5 (https=)
ES2428824T3 (es) Combinaciones útiles de antibióticos de monobactama con inhibidores de beta-lactamasa
ES2371265T3 (es) Amidas de ácido 3-heterociclil-3-hidroxi-2-amino-propiónico y compuestos relacionados que tienen actividad analgésica y/o inmunoestimulante.
RU2009137012A (ru) Аналоги циклопаминлактама и способы их применения
JP2006508036A5 (https=)
RU2004129584A (ru) Производное 8-азапростагландина и агент, содержащий данное соединение в качестве активного ингредиента
JP2010509375A5 (https=)
RU2012102094A (ru) Новые азабициклогексаны
JP2021519776A5 (https=)
RU2001120726A (ru) Комбинация ингибиторов fbpазы и сенсибилизаторов инсулина для лечения диабета
JP2008501018A5 (https=)
RU2004113099A (ru) Четвертичные аммониевые соли омега-аминоалкиламидов r-2- арилпропионовых кислот и содержащие их фармацевтические составы
RU2011110435A (ru) Пролекарства метилгидрофумарата, фармацетические композиции с ними и способы применения
JP2017537940A5 (https=)
JP2002536329A5 (https=)
JP2006511484A5 (https=)
JP2013530179A5 (https=)
EA200800476A1 (ru) Макроциклические ингибиторы вируса гепатита с
JP2009501234A5 (https=)
RU2012116877A (ru) Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы
JP2020512276A5 (https=)
RU2015151129A (ru) Производные фенилоксадиазола в качестве ингибиторов pgds
JP2005533013A5 (https=)
RU2011106356A (ru) Модуляторы рецептора сфингозин-1-фосфата (s1p) и их применение для лечения воспаления мышечной ткани
RU2001107139A (ru) Мускариновые агонисты и антагонисты